Stivarga
/
Stivarga (regorafenib) is a targeted therapy classified as a kinase inhibitor, used for the treatment of metastatic colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma. It is administered as an oral tablet and is available by prescription only. Patients are advised to monitor for potential side effects, including liver problems, and should not use Stivarga if they have severe liver impairment.
FAQs about Stivarga
What should I do if I miss a dose?
If you miss a dose of Stivarga, take it as soon as you remember on the same day. However, if it is almost time for your next dose, skip the missed dose and continue with your regular schedule. Do not take two doses at the same time to make up for a missed dose. This information is provided in the Patient Counseling Information section of the label.
Can I take Stivarga while pregnant or breastfeeding?
Stivarga is not recommended for use during pregnancy due to potential harm to the fetus. Women who are pregnant or may become pregnant should discuss the risks with their healthcare provider. It is also advised that women do not breastfeed while taking Stivarga, as it is not known if the drug passes into breast milk. This information is outlined in the Warnings and Precautions section of the label.
Can I stop taking Stivarga suddenly?
The label does not specifically warn against abrupt discontinuation of Stivarga; however, patients should consult their healthcare provider before stopping the medication. It is important to follow the prescriber\
25
commonly-prescribed
medication.